HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma.

AbstractBACKGROUND:
Primary signet-ring cell carcinoma (SRC) of colorectal and appendiceal origin is a rare entity with an aggressive biology and clinical behavior. The majority of patients develop peritoneal carcinomatosis (PC) early in the disease. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may potentially improve survival.
METHODS:
An observational study of 33 patients with SRC of colorectal or appendiceal origin was identified through a retrospective review of two peritoneal surface malignancy databases between January 1997 and December 2008. Survival analysis was performed using the Kaplan-Meier method.
RESULTS:
Thirty-three patients (18 women (55%); mean age at diagnosis of carcinomatosis, 49 (standard deviation = 12) years) were identified to have SRC, with 15 cases of colorectal and 18 of appendiceal origin. For patients with colonic SRC who underwent complete CRS and HIPEC versus systemic chemotherapy only, the median survival was 13 and 18 months (P = 0.75). For patients with appendiceal SRC who underwent complete CRS and HIPEC versus systemic chemotherapy only, the median survival was 27 and 15 months (P = 0.12).
CONCLUSIONS:
There seems to be less survival benefits after a complete CRS and HIPEC as a curative treatment for PC from colorectal SRC compared with that for non-SRC colorectal adenocarcinoma. However, in patients with appendiceal SRC, long-term survival is a reality after treatment.
AuthorsTerence C Chua, Joerg O W Pelz, Alexander Kerscher, David L Morris, Jesus Esquivel
JournalAnnals of surgical oncology (Ann Surg Oncol) Vol. 16 Issue 10 Pg. 2765-70 (Oct 2009) ISSN: 1534-4681 [Electronic] United States
PMID19641972 (Publication Type: Journal Article)
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Appendiceal Neoplasms (mortality, pathology, therapy)
  • Carcinoma, Signet Ring Cell (mortality, secondary, therapy)
  • Colorectal Neoplasms (mortality, pathology, therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Peritoneal Neoplasms (mortality, secondary, therapy)
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: